A5094241006- Antibiotic Resistance in Bacteria
- Vibrio bacteria research studies
- Mosquito-borne diseases and control
- Viral Infections and Outbreaks Research
- Poxvirus research and outbreaks
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Bacterial biofilms and quorum sensing
- Legionella and Acanthamoeba research
- Zoonotic diseases and public health
- SARS-CoV-2 and COVID-19 Research
- Hepatitis C virus research
Babcock University
2024
Dengue Fever remains a pressing public health concern in the Global South, including Africa, where limited resources, inadequate surveillance, weak systems, climate change, and urbanization exacerbate threat. This review study focuses on strategies to strengthen preparedness, capacity building efforts vector control, system strengthening, community engagement, research. Investing training programs, research initiatives, regional collaboration is vital. Advocacy for increased political...
Yellow fever (YF) remains a significant public health concern in Nigeria, with sporadic outbreaks causing considerable morbidity and mortality. This zoonotic viral disease is transmitted primarily by Aedes mosquitoes, posing constant threat to human populations. Although vaccination efforts have been ongoing for years, still occur, underscoring the need comprehensive approach combat YF. In adopting One Health imperative effective yellow control. recognizes intricate interplay between health,...
Mpox, declared a Public Health Emergency of International Concern by the World Organization (WHO), poses growing global threat. The resurgence, driven highly transmissible and severe clade Ib strain from Democratic Republic Congo, raises concerns about potential pandemic. This narrative review aims to identify actionable strategies mitigate current Mpox outbreak leveraging lessons past health crises, particularly COVID-19, highlight future research priorities essential for preparedness. A...
Recent advancements in the treatment of hepatitis C virus (HCV) infection have significantly advanced goal achieving a C-free world. The introduction direct-acting antivirals (DAAs) has revolutionized treatment, offering over 95% cure rates, shorter durations, and fewer side effects. Pan-genotypic regimens, such as sofosbuvir/velpatasvir, further simplified by being effective across all HCV genotypes. Despite these advancements, substantial challenges persist globally. An estimated 50...